De Giorgi U - Search Results

1

Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab.

Debien V, Marta GN, Agostinetto E, Sirico M, Jacobs F, Molinelli C, Moreau M, Paesmans M, De Giorgi U, Santoro A, Taylor D, Duhoux FP, Botticelli A, Barchiesi G, Speranza I, Lambertini M, Wildiers H, Azambuja E, Piccart M. Debien V, et al. Among authors: de giorgi u. Crit Rev Oncol Hematol. 2023 Oct;190:104089. doi: 10.1016/j.critrevonc.2023.104089. Epub 2023 Aug 9. Crit Rev Oncol Hematol. 2023. PMID: 37562696 Review.

2

Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor?

Banna GL, De Giorgi U, Ferrari B, Castagna L, Alloisio M, Marangolo M, Rosti G, Santoro A. Banna GL, et al. Among authors: de giorgi u. Biol Blood Marrow Transplant. 2006 Oct;12(10):1085-91. doi: 10.1016/j.bbmt.2006.06.008. Biol Blood Marrow Transplant. 2006. PMID: 17084372 Free article. Clinical Trial.

3

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium. du Bois A, et al. Lancet Oncol. 2016 Jan;17(1):78-89. doi: 10.1016/S1470-2045(15)00366-6. Epub 2015 Nov 16. Lancet Oncol. 2016. PMID: 26590673 Free article. Clinical Trial.

4

State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough.

Bersanelli M, Buti S, De Giorgi U, Di Maio M, Giannarelli D, Pignata S, Banna GL. Bersanelli M, et al. Among authors: de giorgi u. Crit Rev Oncol Hematol. 2019 Jul;139:87-90. doi: 10.1016/j.critrevonc.2019.05.003. Epub 2019 May 8. Crit Rev Oncol Hematol. 2019. PMID: 31112887 Free article. Review.

5

Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review.

Cursano MC, Iuliani M, Casadei C, Stellato M, Tonini G, Paganelli G, Santini D, De Giorgi U. Cursano MC, et al. Among authors: de giorgi u. Crit Rev Oncol Hematol. 2020 Feb;146:102864. doi: 10.1016/j.critrevonc.2020.102864. Epub 2020 Jan 7. Crit Rev Oncol Hematol. 2020. PMID: 31986318 Review.

6

A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma.

Lolli C, Altavilla A, Conteduca V, Farolfi A, Casadei C, Schepisi G, Banna GL, De Giorgi U. Lolli C, et al. Among authors: de giorgi u. Crit Rev Oncol Hematol. 2020 Sep;153:103036. doi: 10.1016/j.critrevonc.2020.103036. Epub 2020 Jun 26. Crit Rev Oncol Hematol. 2020. PMID: 32650216 Review.

7

The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives.

Brighi N, Conteduca V, Lolli C, Gurioli G, Schepisi G, Palleschi M, Mariotti M, Casadei C, De Giorgi U. Brighi N, et al. Among authors: de giorgi u. Crit Rev Oncol Hematol. 2021 Jan;157:103199. doi: 10.1016/j.critrevonc.2020.103199. Epub 2020 Dec 13. Crit Rev Oncol Hematol. 2021. PMID: 33316419 Review.

8

Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer.

Palleschi M, Tedaldi G, Sirico M, Virga A, Ulivi P, De Giorgi U. Palleschi M, et al. Among authors: de giorgi u. Int J Mol Sci. 2021 Jul 23;22(15):7884. doi: 10.3390/ijms22157884. Int J Mol Sci. 2021. PMID: 34360649 Free PMC article. Review.

9

Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment.

Gianni C, Palleschi M, Schepisi G, Casadei C, Bleve S, Merloni F, Sirico M, Sarti S, Cecconetto L, Di Menna G, Schettini F, De Giorgi U. Gianni C, et al. Among authors: de giorgi u. Front Oncol. 2022 Aug 8;12:882896. doi: 10.3389/fonc.2022.882896. eCollection 2022. Front Oncol. 2022. PMID: 36003772 Free PMC article. Review.

10

Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer.

Gianni C, Palleschi M, Merloni F, Di Menna G, Sirico M, Sarti S, Virga A, Ulivi P, Cecconetto L, Mariotti M, De Giorgi U. Gianni C, et al. Among authors: de giorgi u. Int J Mol Sci. 2022 Nov 17;23(22):14197. doi: 10.3390/ijms232214197. Int J Mol Sci. 2022. PMID: 36430675 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

511 results

Search Page